Dermata raises $3.4M in private placement of shares and warrants

Dermata Therapeutics, Inc.

Gross proceeds ~$3.4M; net ~$3.2M after expenses; closing expected Aug 18, 2026.
Issued 2,293,608 shares (or pre-funded warrants) plus series E and F warrants for 2,293,608 shares each at $1.46.
Insiders (CEO, CFO, management) bought ~4.9M shares/warrants for ~$2.4M at $1.47 per unit.
Warrants exercisable at $1.46; series E expire 5 years, series F expire 24 months from stockholder approval; potential $6.7M if exercised.
Proceeds for general corporate purposes, including OTC acne kit launch and R&D.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.